BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33735525)

  • 1. Sulfatase 2 (SULF2) Monoclonal Antibody 5D5 Suppresses Human Cholangiocarcinoma Xenograft Growth Through Regulation of a SULF2-Platelet-Derived Growth Factor Receptor Beta-Yes-Associated Protein Signaling Axis.
    Luo X; Campbell NA; He L; O'Brien DR; Singer MS; Lemjabbar-Alaoui H; Ahn KS; Smoot R; Torbenson MS; Rosen SD; Roberts LR
    Hepatology; 2021 Sep; 74(3):1411-1428. PubMed ID: 33735525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet-derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation.
    Smoot RL; Werneburg NW; Sugihara T; Hernandez MC; Yang L; Mehner C; Graham RP; Bronk SF; Truty MJ; Gores GJ
    J Cell Biochem; 2018 Jan; 119(1):824-836. PubMed ID: 28661054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein.
    Saikawa S; Kaji K; Nishimura N; Seki K; Sato S; Nakanishi K; Kitagawa K; Kawaratani H; Kitade M; Moriya K; Namisaki T; Mitoro A; Yoshiji H
    Cancer Lett; 2018 Oct; 434():120-129. PubMed ID: 30031758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma.
    Ilyas SI; Yamada D; Hirsova P; Bronk SF; Werneburg NW; Krishnan A; Salim W; Zhang L; Trushina E; Truty MJ; Gores GJ
    J Biol Chem; 2016 Apr; 291(15):8031-47. PubMed ID: 26826125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma.
    Conboy CB; Yonkus JA; Buckarma EH; Mun DG; Werneburg NW; Watkins RD; Alva-Ruiz R; Tomlinson JL; Guo Y; Wang J; O'Brien D; McCabe CE; Jessen E; Graham RP; Buijsman RC; Vu D; de Man J; Ilyas SI; Truty MJ; Borad M; Pandey A; Gores GJ; Smoot RL
    J Hepatol; 2023 Jan; 78(1):142-152. PubMed ID: 36162702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of Wnt/β-catenin signaling in the mesenchymal stem cells promote metastatic growth and chemoresistance of cholangiocarcinoma.
    Wang W; Zhong W; Yuan J; Yan C; Hu S; Tong Y; Mao Y; Hu T; Zhang B; Song G
    Oncotarget; 2015 Dec; 6(39):42276-89. PubMed ID: 26474277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long non-coding RNA MIR22HG inhibits cell proliferation and migration in cholangiocarcinoma by negatively regulating the Wnt/β-catenin signaling pathway.
    Hu X; Tan Z; Yang Y; Yang P
    J Gene Med; 2019 May; 21(5):e3085. PubMed ID: 30856284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth.
    Hall C; Ehrlich L; Venter J; O'Brien A; White T; Zhou T; Dang T; Meng F; Invernizzi P; Bernuzzi F; Alpini G; Lairmore TC; Glaser S
    Cancer Lett; 2017 Feb; 386():179-188. PubMed ID: 27894959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma.
    Obchoei S; Weakley SM; Wongkham S; Wongkham C; Sawanyawisuth K; Yao Q; Chen C
    Mol Cancer; 2011 Aug; 10():102. PubMed ID: 21871105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells.
    Kitagawa K; Moriya K; Kaji K; Saikawa S; Sato S; Nishimura N; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
    Gene; 2019 May; 698():50-60. PubMed ID: 30822475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of membrane metalloendopeptidase inhibits substance P stimulation of cholangiocarcinoma growth.
    Meng F; DeMorrow S; Venter J; Frampton G; Han Y; Francis H; Standeford H; Avila S; McDaniel K; McMillin M; Afroze S; Guerrier M; Quezada M; Ray D; Kennedy L; Hargrove L; Glaser S; Alpini G
    Am J Physiol Gastrointest Liver Physiol; 2014 May; 306(9):G759-68. PubMed ID: 24603459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracellular Signal-Regulated Kinase 5 Regulates the Malignant Phenotype of Cholangiocarcinoma Cells.
    Gentilini A; Lori G; Caligiuri A; Raggi C; Di Maira G; Pastore M; Piombanti B; Lottini T; Arcangeli A; Madiai S; Navari N; Banales JM; Di Matteo S; Alvaro D; Duwe L; Andersen JB; Tubita A; Tusa I; Di Tommaso L; Campani C; Rovida E; Marra F
    Hepatology; 2021 Oct; 74(4):2007-2020. PubMed ID: 33959996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GSG2 knockdown suppresses cholangiocarcinoma progression by regulating cell proliferation, apoptosis and migration.
    Zhou J; Nie W; Yuan J; Zhang Z; Mi L; Wang C; Huang R
    Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33846801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corilagin suppresses cholangiocarcinoma progression through Notch signaling pathway in vitro and in vivo.
    Gu Y; Xiao L; Ming Y; Zheng Z; Li W
    Int J Oncol; 2016 May; 48(5):1868-76. PubMed ID: 26935808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparan sulfate 6-O-endosulfatases, Sulf1 and Sulf2, regulate glomerular integrity by modulating growth factor signaling.
    Takashima Y; Keino-Masu K; Yashiro H; Hara S; Suzuki T; van Kuppevelt TH; Masu M; Nagata M
    Am J Physiol Renal Physiol; 2016 Mar; 310(5):F395-408. PubMed ID: 26764203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-144 suppresses cholangiocarcinoma cell proliferation and invasion through targeting platelet activating factor acetylhydrolase isoform 1b.
    Yang R; Chen Y; Tang C; Li H; Wang B; Yan Q; Hu J; Zou S
    BMC Cancer; 2014 Dec; 14():917. PubMed ID: 25479763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-494-dependent WDHDI inhibition suppresses epithelial-mesenchymal transition, tumor growth and metastasis in cholangiocarcinoma.
    Liu B; Hu Y; Qin L; Peng XB; Huang YX
    Dig Liver Dis; 2019 Mar; 51(3):397-411. PubMed ID: 30314946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MART-10 represses cholangiocarcinoma cell growth and high vitamin D receptor expression indicates better prognosis for cholangiocarcinoma.
    Chiang KC; Yeh TS; Huang CC; Chang YC; Juang HH; Cheng CT; Pang JS; Hsu JT; Takano M; Chen TC; Kittaka A; Hsiao M; Yeh CN
    Sci Rep; 2017 Mar; 7():43773. PubMed ID: 28256614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenformin inhibits cell proliferation and induces cell apoptosis and autophagy in cholangiocarcinoma.
    Hu S; Ouyang Q; Cheng Q; Wang J; Feng F; Qiao L; Gan W; Shi Y; Wu D; Jiang X
    Mol Med Rep; 2018 Apr; 17(4):6028-6032. PubMed ID: 29436644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.